# Boston Scientific vs Takeda Pharmaceutical: stocks compared

URL: https://funkfolio.com/compare/bsx-vs-tak

> Boston Scientific ($62.4B, P/E 18.2) and Takeda Pharmaceutical ($69.1B, P/E 309) compared: size, valuation, margins, debt, cash and price change.

---

## Boston Scientific vs Takeda Pharmaceutical

Boston Scientific (BSX), health care, and Takeda Pharmaceutical (TAK), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Takeda Pharmaceutical is worth $69.1B on the stock market and Boston Scientific $62.4B: Takeda Pharmaceutical is valued at 11% more. Boston Scientific trades at 18.2 times earnings and Takeda Pharmaceutical at 309; operating margins in their latest fiscal years were 18.0% and 0.14%. Over the past year Boston Scientific's share price has moved -56.0% and Takeda Pharmaceutical's +53.4%.

### Key facts

- **Boston Scientific market value:** $62.4B
- **Takeda Pharmaceutical market value:** $69.1B
- **Boston Scientific P/E:** 18.2
- **Takeda Pharmaceutical P/E:** 309
- **Boston Scientific revenue:** $20.1B FY to 2025-12-31
- **Takeda Pharmaceutical revenue:** $28.2B FY to 2026-03-31
- **Superinvestors holding both:** 0

Market values as of 18 Nov 2026, 07:07 UTC.

Boston Scientific vs Takeda Pharmaceutical: every measure side by side

| Measure | Boston Scientific | Takeda Pharmaceutical |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | Japan |
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size |  |  |
| Market cap | $62.4B lower | $69.1B higher |
| Revenue | $20.1B lower | $28.2B higher |
| Earnings | $2.9B higher | -$954.4M lower |
| Employees | 59,000 higher | 47,029 lower |
| Total assets | $43.7B lower | $97.1B higher |
| Valuation |  |  |
| P/E | 18.2 lower | 309 higher |
| P/S | 3.1 higher | 2.5 lower |
| P/B | 2.4 | — |
| Dividend yield | 0.00% | — |
| Profitability |  |  |
| Operating margin | 18.0% higher | 0.14% lower |
| Balance sheet |  |  |
| Net assets | $24.2B lower | $46.5B higher |
| Total liabilities | $19.2B lower | $50.6B higher |
| Total debt | $11.4B lower | $30.6B higher |
| Cash on hand | $2B lower | $3.7B higher |
| Price change |  |  |
| Today | -1.51% lower | +0.23% higher |
| 1 year | -56.0% lower | +53.4% higher |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Boston Scientific 42.3, Takeda Pharmaceutical 153.0.

- Boston Scientific (BSX)
- Takeda Pharmaceutical (TAK)

Boston Scientific and Takeda Pharmaceutical share prices over one year, rebased to 100: Boston Scientific ends at 42.3, Takeda Pharmaceutical at 153.0.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | BSX | TAK |
| --- | --- | --- |
| Nov 28, 2025 | 99.8 | 102.0 |
| Dec 31, 2025 | 93.7 | 110.3 |
| Jan 30, 2026 | 91.9 | 121.9 |
| Feb 27, 2026 | 75.5 | 132.6 |
| Mar 31, 2026 | 61.7 | 131.0 |
| Apr 30, 2026 | 56.6 | 118.0 |
| May 29, 2026 | 47.5 | 112.9 |
| Jun 30, 2026 | 41.9 | 113.4 |
| Jul 31, 2026 | 45.9 | 120.9 |
| Aug 31, 2026 | 47.5 | 127.2 |
| Sep 30, 2026 | 42.9 | 128.6 |
| Oct 30, 2026 | 41.3 | 147.9 |
| Nov 17, 2026 | 42.3 | 153.0 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (0)

None of the tracked investors.

#### Boston Scientific only (13)

- [Andrew Spokes](https://funkfolio.com/gurus/farallon) 2.6%
- [Lee Ainslie](https://funkfolio.com/gurus/lee-ainslie) 2.3%
- [Primecap team](https://funkfolio.com/gurus/primecap) 1.6%
- [Steven Romick](https://funkfolio.com/gurus/steven-romick) 1.2%
- [Louis Bacon](https://funkfolio.com/gurus/louis-bacon) 0.8%
- [David Shaw (founder)](https://funkfolio.com/gurus/david-shaw) 0.7%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.6%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) 0.4%
- [Dodge & Cox team](https://funkfolio.com/gurus/dodge-and-cox) 0.3%
- [Temasek](https://funkfolio.com/gurus/temasek) 0.3%
- [Paul Tudor Jones](https://funkfolio.com/gurus/paul-tudor-jones) 0.3%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.1%
- [Larry Robbins](https://funkfolio.com/gurus/larry-robbins) 0.1%

#### Takeda Pharmaceutical only (2)

- [Charles Brandes (founder)](https://funkfolio.com/gurus/charles-brandes) 0.5%
- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) &lt;0.1%

Percentages are each holding's share of that investor's reported portfolio. [Who owns BSX](https://funkfolio.com/stock/BSX/superinvestors) · [Who owns TAK](https://funkfolio.com/stock/TAK/superinvestors)

### More on Boston Scientific

- [Boston Scientific (BSX) stock page](https://funkfolio.com/stock/BSX)
- [Boston Scientific market cap](https://funkfolio.com/stock/BSX/market-cap)
- [Boston Scientific revenue](https://funkfolio.com/stock/BSX/revenue)
- [Boston Scientific P/E ratio](https://funkfolio.com/stock/BSX/pe-ratio)
- [Boston Scientific operating margin](https://funkfolio.com/stock/BSX/operating-margin)
- [Boston Scientific total debt](https://funkfolio.com/stock/BSX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Takeda Pharmaceutical

- [Takeda Pharmaceutical (TAK) stock page](https://funkfolio.com/stock/TAK)
- [Takeda Pharmaceutical market cap](https://funkfolio.com/stock/TAK/market-cap)
- [Takeda Pharmaceutical revenue](https://funkfolio.com/stock/TAK/revenue)
- [Takeda Pharmaceutical P/E ratio](https://funkfolio.com/stock/TAK/pe-ratio)
- [Takeda Pharmaceutical operating margin](https://funkfolio.com/stock/TAK/operating-margin)
- [Takeda Pharmaceutical total debt](https://funkfolio.com/stock/TAK/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Boston Scientific against its closest peers

- [Boston Scientific vs Cardinal Health](https://funkfolio.com/compare/bsx-vs-cah)
- [Boston Scientific vs Cencora](https://funkfolio.com/compare/bsx-vs-cor)
- [Boston Scientific vs argenx](https://funkfolio.com/compare/argx-vs-bsx)

#### Takeda Pharmaceutical against its closest peers

- [Takeda Pharmaceutical vs Cencora](https://funkfolio.com/compare/cor-vs-tak)
- [Takeda Pharmaceutical vs Cardinal Health](https://funkfolio.com/compare/cah-vs-tak)
- [Takeda Pharmaceutical vs argenx](https://funkfolio.com/compare/argx-vs-tak)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Boston Scientific or Takeda Pharmaceutical?**

By market value, Takeda Pharmaceutical is the larger: $69.1B against $62.4B for Boston Scientific. By revenue in its latest fiscal year, Takeda Pharmaceutical is the larger: $28.2B against $20.1B for Boston Scientific.

**Which has the higher P/E ratio?**

Takeda Pharmaceutical: 309, against 18.2 for Boston Scientific. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher operating margin?**

Boston Scientific: 18.0%, against 0.14% for Takeda Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.

**Which has more debt?**

Takeda Pharmaceutical: $30.6B, against $11.4B for Boston Scientific. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

**Which superinvestors own both Boston Scientific and Takeda Pharmaceutical?**

None of the tracked superinvestors holds both in their latest 13F filing. 13 hold Boston Scientific and 2 hold Takeda Pharmaceutical.

### Cite this page

Funkfolio, “Boston Scientific vs Takeda Pharmaceutical”, data as of 18 November 2026. https://funkfolio.com/compare/bsx-vs-tak

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
